InvestSMART

Island Pharmaceuticals Limited (ASX:ILA)

ALERT: Price-sensitive ASX Announcement for ILA
Current share price for ILA : $0.425 -0.005 (-1.16%)+
Announcement
Release
27 Jan 2026 8:32AM
Price at Release
$0.430
Full Release
download
Summary
Island Pharmaceuticals Limited reported significant advancements in the development of its Galidesivir antiviral program during the quarter ended 31 December 2025. Key achievements include the confirmation by the FDA that Galidesivir is eligible for development under the Animal Rule, which de-risks the regulatory pathway and positions the company for a Priority Review Voucher upon approval. The company strengthened its US government engagement and expanded its intellectual property estate by securing a new US patent for Galidesivir's use against COVID-19, extending protection until July 2042. Financially, Island raised approximately $1.0 million through option exercises and maintained cash and cash equivalents of $6.87 million as of the end of the quarter, indicating a strong balance sheet to support its ongoing initiatives.
Key Points
  • FDA confirmed Galidesivir's eligibility for development under the Animal Rule.
  • Galidesivir is eligible for a Priority Review Voucher upon approval.
  • Constructive engagement with the FDA to finalize clinical study design.
  • Secured Master Service Agreement with Texas Biomed for non-human primate studies.
  • Joined the Medical Countermeasures Coalition to enhance US market engagement.
  • Expanded US patent protection for Galidesivir until July 2042.
  • Raised approximately $1.0 million from option exercises by directors and shareholders.
  • Cash and cash equivalents stand at $6.87 million at the quarter's end.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.